Ocugen (NASDAQ:OCGN) Sets New 12-Month High – Here’s What Happened

Ocugen, Inc. (NASDAQ:OCGN)’s stock price hit a new 52-week high during trading on Wednesday . The company traded as high as $2.25 and last traded at $2.1650, with a volume of 7793074 shares traded. The stock had previously closed at $1.77.

Key Ocugen News

Here are the key news stories impacting Ocugen this week:

• Positive Sentiment: Oppenheimer initiated coverage with an “Outperform” rating and a $10 price target, implying large upside vs. the current share price — a clear analyst catalyst that likely lifted sentiment and buying interest. Oppenheimer Initiates Coverage
• Positive Sentiment: HC Wainwright raised near-term quarterly EPS forecasts (Q1–Q4 2026 and FY2026) modestly, trimming expected losses for FY2026 (from -$0.29 to -$0.24), which signals improving near-term operating outlook. This can support optimism among short-term investors. HC Wainwright Estimates on MarketBeat
• Positive Sentiment: Clinical progress: Ocugen reported 2025 results and updates across its gene-therapy pipeline and announced completion of enrollment in the Phase 3 trial of OCU400 — both are operational catalysts that de-risk development milestones and attract biotech investor interest. Ocugen reports 2025 results OCU400 enrollment complete
• Neutral Sentiment: Broader coverage pieces compare Ocugen to peers (sector performance articles); useful for context but less likely to move the stock materially on their own. Sector comparison article
• Neutral Sentiment: HC Wainwright published an optimistic long-range FY2030 EPS projection ($1.04), which is highly speculative and may help longer-term bull narratives but has limited near-term valuation impact. HC Wainwright FY2030 note
• Negative Sentiment: HC Wainwright cut FY2027–FY2029 estimates (notably FY2029 from $0.84 to $0.26 and FY2028 to -$0.10), reflecting more conservative long-term assumptions and adding uncertainty to the multi‑year growth story. That could temper enthusiasm among some investors. HC Wainwright estimate revisions
• Negative Sentiment: Seeking Alpha published a downgrade piece following the OCU410 data release, which could spur short-term selling or increased short interest from skeptical investors. Seeking Alpha downgrade

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on OCGN shares. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Ocugen in a research report on Thursday, January 22nd. Chardan Capital reissued a “buy” rating and issued a $7.00 target price on shares of Ocugen in a report on Thursday, March 5th. Oppenheimer began coverage on Ocugen in a report on Wednesday. They set an “outperform” rating and a $10.00 price objective on the stock. Finally, Wall Street Zen downgraded Ocugen from a “hold” rating to a “sell” rating in a research report on Saturday. Three investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $8.00.

Ocugen Stock Performance

The firm has a market capitalization of $746.30 million, a P/E ratio of -9.94 and a beta of 2.75. The company has a 50-day moving average of $1.59 and a 200-day moving average of $1.44. The company has a current ratio of 1.06, a quick ratio of 1.06 and a debt-to-equity ratio of 8.04.

Ocugen (NASDAQ:OCGN) last released its quarterly earnings results on Wednesday, March 4th. The company reported ($0.06) EPS for the quarter, meeting analysts’ consensus estimates of ($0.06). Ocugen had a negative return on equity of 2,626.38% and a negative net margin of 1,192.18%.The firm had revenue of ($0.19) million for the quarter, compared to analyst estimates of $0.86 million. On average, equities analysts anticipate that Ocugen, Inc. will post -0.2 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the company. Creative Planning acquired a new position in shares of Ocugen in the 2nd quarter worth approximately $57,000. Catalyst Funds Management Pty Ltd bought a new position in Ocugen during the second quarter worth $130,000. XTX Topco Ltd acquired a new position in Ocugen in the second quarter valued at $203,000. Rinkey Investments raised its position in shares of Ocugen by 1.2% in the 2nd quarter. Rinkey Investments now owns 1,179,006 shares of the company’s stock worth $1,144,000 after acquiring an additional 14,500 shares in the last quarter. Finally, Jump Financial LLC acquired a new position in shares of Ocugen in the 2nd quarter valued at about $57,000. Institutional investors own 10.27% of the company’s stock.

About Ocugen

Ocugen Inc is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing gene therapies to treat rare inherited retinal diseases, as well as vaccines designed to address unmet needs in infectious diseases. Headquartered in Malvern, Pennsylvania, the company applies its proprietary gene therapy platform to create novel treatments aimed at preserving and restoring vision, while leveraging strategic partnerships to broaden its vaccine pipeline.

In its gene therapy portfolio, Ocugen is advancing multiple programs targeting retinal disorders.